Treatment of Myelofibrosis with JAK Inhibitors May Increase Risk for Aggressive Lymphoma

A study published in Blood showed that, based on a retrospective review of data, patients with myelofibrosis who have a pre-existing B-cell clone in their bone marrow and who are being treated with JAK1/2 inhibitors may be at an increased risk of developing aggressive B-cell lymphoma.